Blenrep
CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma
May 23, 2025Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
GSK’s application for Blenrep for MM treatment accepted for EMA review
July 19, 2024Medical Communications Blenrep, EMA, GSK, Oncology
GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
March 7, 2024Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
